It is reported in the journal article titled "the effect of antiplatelet agents on bleeding related complications following ureteroscopy, " nine of 314 patients from the study group had ureteroscopy performed (while receiving anti-platelet therapy) using one of five listed scopes including an olympus urf-p3, and experienced adverse events.Of the nine patients experiencing adverse events, five patients experienced what was classified as a significant bleeding event:(1) procedure termination explicitly due to bleeding and difficult visualization resulting in a second operative intervention; (2) unplanned, immediate postoperative admission for bleeding; (3) ed visit for hematuria; (4) subsequent hospital admission for hematuria management (after dismissal home post-procedure); and 5) unplanned return to the or for evaluation of ongoing bleeding.No patient required a blood transfusion.One patient experienced a non-significant bleeding event, with no treatment required.Two patients were re-admitted post-procedure for fever/bacteremia (treatment not specified).One patient was re-admitted post procedure for abdominal pain, nausea and vomiting (treatment not specified).This is a retrospective study from 2009-2016 and there is no specific information regarding which scope was used in each case.This report is being submitted to report the potential that an olympus device could have caused or contributed to an adverse event in one of the nine patients who experienced an adverse event.There is no report that the urf-p3 malfunctioned in any way.
|